Hutch News

Results per Page: 20
  • 5
  • 10
  • 20
  • 50
  • 100

New Science Spotlight Articles

Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
10 NEW January 20, 2020
Pembrolizumab treatment for Merkel cell carcinoma

Pembrolizumab treatment for Merkel cell carcinoma

From the Nghiem Laboratory, Clinical Research Division
Science Spotlight - March 18, 2019
Seattle team pivotal to FDA OK on drug for rare skin cancer

Seattle team pivotal to FDA OK on drug for rare skin cancer

UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Releases - December 20, 2018
Triple therapy for rare skin cancer shows promise in small, early-stage trial

Triple therapy for rare skin cancer shows promise in small, early-stage trial

Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Hutch News - May 31, 2017
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Hutch News - April 03, 2017
Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

Benefit seen in nearly one-third of patients ‘with no hope at all of surviving’ their treatment-resistant Merkel cell carcinoma
Hutch News - March 24, 2017
A new blood test detects recurrence of rare skin cancer

A new blood test detects recurrence of rare skin cancer

$200 assay can accurately signal return of Merkel cell carcinoma — in some cases catching tumors earlier than expensive imaging
Hutch News - December 12, 2016
Last Modified, August 15, 2019